WCLC 2024
Advertisement
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The three-year survival rate in the 2020 cohort of patients with NSCLC was more than double that of the 2000 cohort.
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
The 5-year scoping review provided insights on the different abstracts and educational content presented at 12 meetings.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Gene Ho, MPH, discusses real-world data on adverse events and survival outcomes with immunotherapy for NSCLC.
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Robert E. Merritt, MD, MBA, FACS, discusses the analysis he presented at the IASLC 2024 World Conference on Lung Cancer.
The real-world study was presented at the IASLC 2024 World Conference on Lung Cancer.
Dr. Rolfo discusses results of an analysis that evaluated the impact of BMI on TTFields therapy.
Dr. Leighl explains PALOMA-3 data presented at the IASLC 2024 World Conference on Lung Cancer.
The trial is investigating nogapendekin alfa inbakicept-pmln in combination with immune checkpoint inhibitor therapy.
Researchers shared an updated safety analysis from the trial at the IASLC 2024 World Conference on Lung Cancer.
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.